鶹ýӰ

FDA Approves TriClip; Fortified Eggs vs Cholesterol; Impella Maker Chided

— Recent developments of interest in cardiovascular medicine

MedpageToday
Cardio Break over a computer rendering of a heart.

Abbott said its snagged FDA approval for treating for tricuspid regurgitation.

Medtronic announced that the FDA approved the , featuring a larger diamond-shaped frame design for easier access to coronary arteries, for people with symptomatic severe aortic stenosis.

Centers adopting (TAVR) reported shorter hospital stays and decreased procedure times without an increase in safety events. (European Heart Journal)

A simple new ECG criterion -- time to notch in lead I >75 msec -- was validated for . (JAMA Cardiology)

Pediatric in-hospital cardiac arrest outcomes depended on the length of the . (Circulation)

Laypeople explained why they would be : men feared accusations of sexual behavior, and women did not want to cause physical injury. (Circulation: Cardiovascular Quality and Outcomes)

has a particularly strong link with subsequent heart disease in women, according to research that will be presented at the American College of Cardiology (ACC) meeting.

Also from ACC, a small trial found that regularly eating did not hurt cholesterol levels over 4 months.

A small but significant ventricular arrhythmia risk may be applicable across . (European Journal of Preventive Cardiology)

People with type 2 diabetes were at greater risk of developing arrhythmias if they had . (Heart)

did not put heart attack patients undergoing percutaneous coronary intervention at increased risk of death and other poor outcomes, a single-center registry showed. (Clinical Cardiology)

Abiomed is under criticism for not notifying the FDA earlier about the perforation risk associated with its . (New York Times)

FDA cleared Eko Health's AI algorithm for quickly from a digital stethoscope alone, the company said.

Artificial intelligence might boost the reliability of based on noninvasive 99mTc-scintigraphy. (Lancet Digital Health)

Real-world results so far have been favorable for in treating right ventricular outflow tract pulmonary regurgitation. (Journal of the American College of Cardiology)

In a phase II trial of people with inoperable , macitentan (Opsumit) reduced pulmonary vascular resistance. (Lancet Respiratory Medicine)

Environmental exposure to was linked to cancer mortality but not all-cause or cardiovascular mortality. (JAMA Network Open)

  • author['full_name']

    Nicole Lou is a reporter for MedPage Today, where she covers cardiology news and other developments in medicine.